RAPP

Announcements

Nothing here yet

Daily updates

• Rapport Therapeutics is evaluating RAP-219 in a Phase 2a trial for bipolar mania, with topline data expected in October 2026. The study is assessing safety, tolerability, and clinical efficacy, with the readout expected to provide early proof-of-concept evidence for the program.Oct 4, 2026

FDA designations

Nothing here yet

News

• Rapport Therapeutics accelerated RAP-219 Phase 3 program and expanded epilepsy portfolioJan 7, 2026
• Rapport announces positive topline results from Phase 2a clinical trial of RAP-219 in patients with focal onset seizuresSep 8, 2025